Morgan Stanley Reiterates Equal-Weight Rating on Neurocrine Biosciences, Inc. (NBIX)

Market Context

Neurocrine Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $150.82 with a market capitalization of $15.4B. The stock has gained 13.5% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurocrine Biosciences, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Neurocrine Biosciences, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 13, 2026	Morgan Stanley	Equal-Weight	N/A
Aug 03, 2026	Truist Securities	Buy	N/A
Aug 03, 2026	Wedbush	Outperform	N/A
Aug 03, 2026	Canaccord Genuity	Buy	N/A
Jul 31, 2026	Cantor Fitzgerald	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View NBIX Stock Page